RecruitingPhase 3NCT03772028
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy
Sponsor
The Netherlands Cancer Institute
Enrollment
538 participants
Start Date
Jan 1, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria2
- candidate for primary CRS
- histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer
Exclusion Criteria4
- history of previous malignancies within 5 years prior to inclusion
- FIGO stage IV disease
- complete primary cytoreduction is impossible
- prior treatment for the current malignancy
Interventions
DRUGcisplatin
HIPEC with cisplatin after cytoreductive surgery
Locations(28)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03772028
Related Trials
Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology
NCT071674331 location
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT074245475 locations
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
NCT064125101 location
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT0465706879 locations